Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1386
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoger, Simon D-
dc.contributor.otherGaillard, Carlo-
dc.contributor.otherBock, A.H.-
dc.contributor.otherCarrera, F.-
dc.contributor.otherEckardt, K.U.-
dc.contributor.otherVan Wyck, David-
dc.contributor.otherBansal, S.S.-
dc.contributor.otherCronin, M.-
dc.contributor.otherMeier, Y.-
dc.contributor.otherLarroque, S.-
dc.contributor.otherMacdougall, I.C.-
dc.date.accessioned2019-05-07T06:09:10Zen
dc.date.available2019-05-07T06:09:10Zen
dc.date.issued2016-06-
dc.identifier.citation11(6):e0157063en
dc.identifier.issn1932-6203en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1386en
dc.description.abstractHepcidin is the key regulator of iron homeostasis but data are limited regarding its temporal response to iron therapy, and response to intravenous versus oral iron. In the 56-week, open-label, multicenter, prospective, randomized FIND-CKD study, 626 anemic patients with non-dialysis dependent chronic kidney disease (ND-CKD) and iron deficiency not receiving an erythropoiesis stimulating agent were randomized (1:1:2) to intravenous ferric carboxymaltose (FCM), targeting higher (400-600mug/L) or lower (100-200mug/L) ferritin, or to oral iron. Serum hepcidin levels were measured centrally in a subset of 61 patients. Mean (SD) baseline hepcidin level was 4.0(3.5), 7.3(6.4) and 6.5(5.6) ng/mL in the high ferritin FCM (n = 17), low ferritin FCM (n = 16) and oral iron group (n = 28). The mean (SD) endpoint value (i.e. the last post-baseline value) was 26.0(9.1),15.7(7.7) and 16.3(11.0) ng/mL, respectively. The increase in hepcidin from baseline was significantly smaller with low ferritin FCM or oral iron vs high ferritin FCM at all time points up to week 52. Significant correlations were found between absolute hepcidin and ferritin values (r = 0.65, p<0.001) and between final post-baseline increases in both parameters (r = 0.70, p<0.001). The increase in hepcidin levels over the 12-month study generally mirrored the cumulative iron dose in each group. Hepcidin and transferrin saturation (TSAT) absolute values showed no correlation, although there was an association between final post-baseline increases (r = 0.42, p<0.001). Absolute values (r = 0.36, p = 0.004) and final post-baseline increases of hepcidin and hemoglobin (p = 0.30, p = 0.030) correlated weakly. Baseline hepcidin levels were not predictive of a hematopoietic response to iron therapy. In conclusion, hepcidin levels rose in response to either intravenous or oral iron therapy, but the speed and extent of the rise was greatest with intravenous iron targeting a higher ferritin level. However neither the baseline level nor the change in hepcidin was able to predict response to therapy in this cohort.en
dc.description.sponsorshipRenalen
dc.subjectKidney Diseaseen
dc.subjectDrug Therapyen
dc.titleHepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trialen
dc.typeJournal Articleen
dc.identifier.doi10.1371/journal.pone.0157063en
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/27276035en
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesGosford Hospitalen
dc.identifier.journaltitlePLoS ONEen
dc.type.studyortrialMulticentre Studiesen
dc.originaltypeTexten
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
Appears in Collections:Renal Medicine
Show simple item record

Page view(s)

26
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.